Kezar Life Sciences Inc. (KZR)’s Financial Results Comparing With Minerva Neurosciences Inc. (NASDAQ:NERV)

Kezar Life Sciences Inc. (NASDAQ:KZR) and Minerva Neurosciences Inc. (NASDAQ:NERV) compete against each other in the Biotechnology sector. We will compare them and contrast their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kezar Life Sciences Inc. N/A 0.00 19.68M -1.05 0.00
Minerva Neurosciences Inc. N/A 0.00 36.81M -1.19 0.00

In table 1 we can see Kezar Life Sciences Inc. and Minerva Neurosciences Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us Kezar Life Sciences Inc. and Minerva Neurosciences Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Kezar Life Sciences Inc. 0.00% 0% 0%
Minerva Neurosciences Inc. 0.00% -31.7% -22%

Liquidity

Kezar Life Sciences Inc.’s Current Ratio and Quick Ratio are 32.9 and 32.9 respectively. The Current Ratio and Quick Ratio of its competitor Minerva Neurosciences Inc. are 26.2 and 26.2 respectively. Kezar Life Sciences Inc. therefore has a better chance of paying off short and long-term obligations compared to Minerva Neurosciences Inc.

Institutional & Insider Ownership

The shares of both Kezar Life Sciences Inc. and Minerva Neurosciences Inc. are owned by institutional investors at 47.5% and 79.9% respectively. 22.8% are Kezar Life Sciences Inc.’s share held by insiders. Comparatively, Minerva Neurosciences Inc. has 0.1% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kezar Life Sciences Inc. -9.94% 16.22% 45.19% 0% 0% 50.59%
Minerva Neurosciences Inc. 0.51% -22.59% -18.46% -5.92% 41.96% 31.4%

For the past year Kezar Life Sciences Inc.’s stock price has bigger growth than Minerva Neurosciences Inc.

Summary

Kezar Life Sciences Inc. beats on 6 of the 6 factors Minerva Neurosciences Inc.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The companyÂ’s lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The companyÂ’ preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of ParkinsonÂ’s disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.